Poly Medicure
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
May 25 (Reuters) - Poly Medicure Ltd PLMD.NS:
POLY MEDICURE LTD - RECOMMENDS DIVIDEND OF 3.50 RUPEES PER SHARE
POLY MEDICURE MARCH-QUARTER CONSOL NET PROFIT 662.9 MILLION RUPEES
POLY MEDICURE MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 5.35 BILLION RUPEES
Source text: ID:nBSE3zvdQY
Further company coverage: PLMD.NS
(([email protected];))
May 25 (Reuters) - Poly Medicure Ltd PLMD.NS:
POLY MEDICURE LTD - RECOMMENDS DIVIDEND OF 3.50 RUPEES PER SHARE
POLY MEDICURE MARCH-QUARTER CONSOL NET PROFIT 662.9 MILLION RUPEES
POLY MEDICURE MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 5.35 BILLION RUPEES
Source text: ID:nBSE3zvdQY
Further company coverage: PLMD.NS
(([email protected];))
April 30 (Reuters) - Poly Medicure Ltd PLMD.NS:
UNIT BUYS 100% EQUITY IN MEDYNEO
TOTAL CONSIDERATION FOR ACQUISITION IS BRAZILIAN REAIS 180,000
Source text: ID:nBSE9ZB6Nb
Further company coverage: PLMD.NS
(([email protected];;))
April 30 (Reuters) - Poly Medicure Ltd PLMD.NS:
UNIT BUYS 100% EQUITY IN MEDYNEO
TOTAL CONSIDERATION FOR ACQUISITION IS BRAZILIAN REAIS 180,000
Source text: ID:nBSE9ZB6Nb
Further company coverage: PLMD.NS
(([email protected];;))
Feb 5 (Reuters) - Poly Medicure Ltd PLMD.NS:
POLY MEDICURE LTD DEC-QUARTER CONSOL NET PROFIT 709.3 MILLION RUPEES
POLY MEDICURE LTD DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 4.94 BILLION RUPEES
Source text: [ID:]
Further company coverage: PLMD.NS
(([email protected];))
Feb 5 (Reuters) - Poly Medicure Ltd PLMD.NS:
POLY MEDICURE LTD DEC-QUARTER CONSOL NET PROFIT 709.3 MILLION RUPEES
POLY MEDICURE LTD DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 4.94 BILLION RUPEES
Source text: [ID:]
Further company coverage: PLMD.NS
(([email protected];))
Sept 4 (Reuters) - Poly Medicure Ltd PLMD.NS:
SIGNS SPA WITH WELLING HOLDINGS B.V.
Source text: ID:nBSE504CZK
Further company coverage: PLMD.NS
(([email protected];))
Sept 4 (Reuters) - Poly Medicure Ltd PLMD.NS:
SIGNS SPA WITH WELLING HOLDINGS B.V.
Source text: ID:nBSE504CZK
Further company coverage: PLMD.NS
(([email protected];))
Aug 20 (Reuters) - Poly Medicure Ltd PLMD.NS:
NCLT APPROVES POLY MEDICURE'S PLAN FOR HIMALAYAN MINERAL WATERS
ACQUISITION COST SET AT 331.5 MILLION RUPEES
Source text: ID:nBSE683dPf
Further company coverage: PLMD.NS
(([email protected];;))
Aug 20 (Reuters) - Poly Medicure Ltd PLMD.NS:
NCLT APPROVES POLY MEDICURE'S PLAN FOR HIMALAYAN MINERAL WATERS
ACQUISITION COST SET AT 331.5 MILLION RUPEES
Source text: ID:nBSE683dPf
Further company coverage: PLMD.NS
(([email protected];;))
** Shares of Poly Medicure PLMD.NS rise 3.7% to 2,883.60
** Stock set to gain for third straight session
** Medical equipment maker's Q4 consol net profit rose 34.3% Y/Y, revenue up 16.6% Y/Y
** Q4 EBITDA margin at 27.1% vs 25.5% year ago
** Trading vols at 410,591 shares, over 2x the 30-day average
** PLMD up ~10% YTD
(Reporting by Vijay Malkar)
(([email protected];))
** Shares of Poly Medicure PLMD.NS rise 3.7% to 2,883.60
** Stock set to gain for third straight session
** Medical equipment maker's Q4 consol net profit rose 34.3% Y/Y, revenue up 16.6% Y/Y
** Q4 EBITDA margin at 27.1% vs 25.5% year ago
** Trading vols at 410,591 shares, over 2x the 30-day average
** PLMD up ~10% YTD
(Reporting by Vijay Malkar)
(([email protected];))
April 1 (Reuters) - AMPIN ENERGY:
AMPIN ENERGY TRANSITION INKS PARTNERSHIP WITH POLY MEDICURE FOR 10 MW SOLAR PROJECT IN HARYANA- STATEMENT
(([email protected];))
April 1 (Reuters) - AMPIN ENERGY:
AMPIN ENERGY TRANSITION INKS PARTNERSHIP WITH POLY MEDICURE FOR 10 MW SOLAR PROJECT IN HARYANA- STATEMENT
(([email protected];))
March 11 (Reuters) - Poly Medicure Ltd PLMD.NS:
RECEIVES MDR CERTIFICATION FOR 54 PRODUCTS
Source text: ID:nBSEbDskCZ
Further company coverage: PLMD.NS
(([email protected];;))
March 11 (Reuters) - Poly Medicure Ltd PLMD.NS:
RECEIVES MDR CERTIFICATION FOR 54 PRODUCTS
Source text: ID:nBSEbDskCZ
Further company coverage: PLMD.NS
(([email protected];;))
Feb 3 (Reuters) - Poly Medicure Ltd PLMD.NS:
POLY MEDICURE DEC-QUARTER CONSOL NET PROFIT 852.3 MILLION RUPEES
POLY MEDICURE DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 4.24 BILLION RUPEES
Source text: ID:nBSE7JMKfk
Further company coverage: PLMD.NS
(([email protected];;))
Feb 3 (Reuters) - Poly Medicure Ltd PLMD.NS:
POLY MEDICURE DEC-QUARTER CONSOL NET PROFIT 852.3 MILLION RUPEES
POLY MEDICURE DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 4.24 BILLION RUPEES
Source text: ID:nBSE7JMKfk
Further company coverage: PLMD.NS
(([email protected];;))
Jan 10 (Reuters) - Poly Medicure Ltd PLMD.NS:
POLY MEDICURE LTD - CO AND AMPIN C&I POWER ENTER JOINT VENTURE AGREEMENT
POLY MEDICURE LTD - CO TO OWN 26% OF JOINT VENTURE COMPANY
POLY MEDICURE LTD - JV TO SET UP SOLAR POWER PROJECT IN HARYANA
Source text: ID:nBSE8cYMzt
Further company coverage: PLMD.NS
(([email protected];;))
Jan 10 (Reuters) - Poly Medicure Ltd PLMD.NS:
POLY MEDICURE LTD - CO AND AMPIN C&I POWER ENTER JOINT VENTURE AGREEMENT
POLY MEDICURE LTD - CO TO OWN 26% OF JOINT VENTURE COMPANY
POLY MEDICURE LTD - JV TO SET UP SOLAR POWER PROJECT IN HARYANA
Source text: ID:nBSE8cYMzt
Further company coverage: PLMD.NS
(([email protected];;))
** Shares of active pharmaceutical ingredients maker Orchid Pharma ORCD.NS rise 4.8% to 1,522.35 rupees
** Co posts a 37.5% rise in Sept-qtr consolidated profit at 272.4 million rupees ($3.2 mln); income from ops rose 12%
** Avg rating of three analysts covering ORCD at "strong buy" vs "hold" for peers Natco Pharma NATP.NS and Poly Medicure PLMD.NS
** ORCD's median PT is at 1,710 rupees - LSEG data
** Stock up ~114% so far this year vs a 76% and 85% rise in NATP and PLMD
($1 = 84.3930 Indian rupees)
(Reporting by Dimpal Gulwani in Bengaluru)
** Shares of active pharmaceutical ingredients maker Orchid Pharma ORCD.NS rise 4.8% to 1,522.35 rupees
** Co posts a 37.5% rise in Sept-qtr consolidated profit at 272.4 million rupees ($3.2 mln); income from ops rose 12%
** Avg rating of three analysts covering ORCD at "strong buy" vs "hold" for peers Natco Pharma NATP.NS and Poly Medicure PLMD.NS
** ORCD's median PT is at 1,710 rupees - LSEG data
** Stock up ~114% so far this year vs a 76% and 85% rise in NATP and PLMD
($1 = 84.3930 Indian rupees)
(Reporting by Dimpal Gulwani in Bengaluru)
Oct 28 (Reuters) - Poly Medicure Ltd PLMD.NS:
POLY MEDICURE SEPT-QUARTER CONSOL NET PROFIT 874.5 MILLION RUPEES
POLY MEDICURE SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 4.2 BILLION RUPEES
Source text: ID:nNSE2MmXXK
Further company coverage: PLMD.NS
(([email protected];))
Oct 28 (Reuters) - Poly Medicure Ltd PLMD.NS:
POLY MEDICURE SEPT-QUARTER CONSOL NET PROFIT 874.5 MILLION RUPEES
POLY MEDICURE SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 4.2 BILLION RUPEES
Source text: ID:nNSE2MmXXK
Further company coverage: PLMD.NS
(([email protected];))
July 22 (Reuters) - Poly Medicure Ltd PLMD.NS:
RE-APPOINTS HIMANSHU BAID AS MD
RE-APPOINTS RISHI BAID AS JOINT MD
Source text for Eikon: ID:nNSE8z4S9h
Further company coverage: PLMD.NS
(([email protected];;))
July 22 (Reuters) - Poly Medicure Ltd PLMD.NS:
RE-APPOINTS HIMANSHU BAID AS MD
RE-APPOINTS RISHI BAID AS JOINT MD
Source text for Eikon: ID:nNSE8z4S9h
Further company coverage: PLMD.NS
(([email protected];;))
March 8 (Reuters) - Poly Medicure Ltd PLMD.NS:
APPROVED RAISING OF FUNDS UP TO 8 BILLION RUPEES
Source text for Eikon: ID:nBSE33THzZ
Further company coverage: PLMD.NS
(([email protected];))
March 8 (Reuters) - Poly Medicure Ltd PLMD.NS:
APPROVED RAISING OF FUNDS UP TO 8 BILLION RUPEES
Source text for Eikon: ID:nBSE33THzZ
Further company coverage: PLMD.NS
(([email protected];))
March 4 (Reuters) - Poly Medicure Ltd PLMD.NS:
TO CONSIDER PROPOSAL FOR RAISING OF FUNDS
Source text for Eikon: ID:nBSE719Nqz
Further company coverage: PLMD.NS
(([email protected];))
March 4 (Reuters) - Poly Medicure Ltd PLMD.NS:
TO CONSIDER PROPOSAL FOR RAISING OF FUNDS
Source text for Eikon: ID:nBSE719Nqz
Further company coverage: PLMD.NS
(([email protected];))
Jan 31 (Reuters) - Poly Medicure Ltd PLMD.NS:
POLY MEDICURE DEC-QUARTER CONSOL NET PROFIT 650.2 MILLION RUPEES VERSUS 500.1 MILLION RUPEES
POLY MEDICURE DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 3.4 BILLION RUPEES VERSUS 2.85 BILLION RUPEES
Source text for Eikon: ID:nBSE7CV3yY
Further company coverage: PLMD.NS
(([email protected];))
Jan 31 (Reuters) - Poly Medicure Ltd PLMD.NS:
POLY MEDICURE DEC-QUARTER CONSOL NET PROFIT 650.2 MILLION RUPEES VERSUS 500.1 MILLION RUPEES
POLY MEDICURE DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 3.4 BILLION RUPEES VERSUS 2.85 BILLION RUPEES
Source text for Eikon: ID:nBSE7CV3yY
Further company coverage: PLMD.NS
(([email protected];))
** Shares of Poly Medicure PLMD.NS rise as much as 9.50% to 1,575 rupees, a record high
** Brokerage Investec initiates coverage with "buy", sets target price set at 1,690 rupees, an implied upside of 18.7%
** Largest Indian exporter of medical devices set for strong earnings trajectory due to multiple industry tailwinds such as govt support, import substitution and China +1 shift in export markets- Investec
** Brokerage adds PLMD's foray into renal (kidney) care, rising U.S. presence to aid revenue diversification
** Says PLMD's plans to expand capacity, strong execution track record will support growth
** Trading volume at 624,802 shares as of 11:01 a.m. IST, more than twice the 30-day avg - Refinitiv data
** PLMD up ~66% in 2023 so far, including session's gains
(Reporting by Bharath Rajeswaran in Bengaluru)
(([email protected]; +91 9769003463))
** Shares of Poly Medicure PLMD.NS rise as much as 9.50% to 1,575 rupees, a record high
** Brokerage Investec initiates coverage with "buy", sets target price set at 1,690 rupees, an implied upside of 18.7%
** Largest Indian exporter of medical devices set for strong earnings trajectory due to multiple industry tailwinds such as govt support, import substitution and China +1 shift in export markets- Investec
** Brokerage adds PLMD's foray into renal (kidney) care, rising U.S. presence to aid revenue diversification
** Says PLMD's plans to expand capacity, strong execution track record will support growth
** Trading volume at 624,802 shares as of 11:01 a.m. IST, more than twice the 30-day avg - Refinitiv data
** PLMD up ~66% in 2023 so far, including session's gains
(Reporting by Bharath Rajeswaran in Bengaluru)
(([email protected]; +91 9769003463))
Aug 7 (Reuters) - Poly Medicure Ltd PLMD.NS:
INDIA'S POLY MEDICURE JUNE-QUARTER CONSOL NET PROFIT 627 MILLION RUPEES VERSUS PROFIT 269.6 MILLION RUPEES
POLY MEDICURE JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 3.21 BILLION RUPEES VERSUS 2.49 BILLION RUPEES
Source text for Eikon: ID:nBSEbZLSTG
Further company coverage: PLMD.NS
(([email protected];))
Aug 7 (Reuters) - Poly Medicure Ltd PLMD.NS:
INDIA'S POLY MEDICURE JUNE-QUARTER CONSOL NET PROFIT 627 MILLION RUPEES VERSUS PROFIT 269.6 MILLION RUPEES
POLY MEDICURE JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 3.21 BILLION RUPEES VERSUS 2.49 BILLION RUPEES
Source text for Eikon: ID:nBSEbZLSTG
Further company coverage: PLMD.NS
(([email protected];))
May 9 (Reuters) - Poly Medicure Ltd PLMD.NS:
DIVIDEND 3 RUPEES PER SHARE
MARCH-QUARTER CONSOL NET PROFIT 588.1 MILLION RUPEES VERSUS PROFIT 361.7 MILLION RUPEES
POLY MEDICURE LTD MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 3.07 BILLION RUPEES VERSUS 2.58 BILLION RUPEES
Source text for Eikon: ID:nBSE9g32Mk
Further company coverage: PLMD.NS
(([email protected];))
May 9 (Reuters) - Poly Medicure Ltd PLMD.NS:
DIVIDEND 3 RUPEES PER SHARE
MARCH-QUARTER CONSOL NET PROFIT 588.1 MILLION RUPEES VERSUS PROFIT 361.7 MILLION RUPEES
POLY MEDICURE LTD MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 3.07 BILLION RUPEES VERSUS 2.58 BILLION RUPEES
Source text for Eikon: ID:nBSE9g32Mk
Further company coverage: PLMD.NS
(([email protected];))
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Poly Medicure do?
Poly Medicure Limited is a renowned Indian company and exporter specializing in high-quality medical devices. With state-of-the-art manufacturing facilities globally, the company ensures top-notch healthcare products.
Who are the competitors of Poly Medicure?
Poly Medicure major competitors are TTK Healthcare, 3B Blackbio Dx, Nureca, QMS Medi Allied Ser., Medplus Health Serv., Jeena Sikho Lifecare, Cupid. Market Cap of Poly Medicure is ₹17,387 Crs. While the median market cap of its peers are ₹1,414 Crs.
Is Poly Medicure financially stable compared to its competitors?
Poly Medicure seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Poly Medicure pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Poly Medicure latest dividend payout ratio is 10.48% and 3yr average dividend payout ratio is 12.56%
How has Poly Medicure allocated its funds?
Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments
How strong is Poly Medicure balance sheet?
Balance sheet of Poly Medicure is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Poly Medicure improving?
The profit is oscillating. The profit of Poly Medicure is ₹315 Crs for TTM, ₹339 Crs for Mar 2025 and ₹258 Crs for Mar 2024.
Is the debt of Poly Medicure increasing or decreasing?
Yes, The net debt of Poly Medicure is increasing. Latest net debt of Poly Medicure is ₹254 Crs as of Mar-26. This is greater than Mar-25 when it was -₹124.84 Crs.
Is Poly Medicure stock expensive?
Poly Medicure is not expensive. Latest PE of Poly Medicure is 53.97, while 3 year average PE is 61.76. Also latest EV/EBITDA of Poly Medicure is 39.87 while 3yr average is 44.28.
Has the share price of Poly Medicure grown faster than its competition?
Poly Medicure has given better returns compared to its competitors. Poly Medicure has grown at ~10.98% over the last 3yrs while peers have grown at a median rate of 1.17%
Is the promoter bullish about Poly Medicure?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Poly Medicure is 62.42% and last quarter promoter holding is 62.42%.
Are mutual funds buying/selling Poly Medicure?
The mutual fund holding of Poly Medicure is increasing. The current mutual fund holding in Poly Medicure is 8.84% while previous quarter holding is 8.14%.